Navigation Links
Early Detection Push from New Alzheimer's Disease Discussion Group Points to Advances by Startup Companies, Including Louisville-Based Neuronetrix, Inc.
Date:12/28/2007

LOUISVILLE, Ky., Dec. 28 /PRNewswire/ -- Recent discussions about screening for Alzheimer's disease have begun to stimulate interest in advanced diagnostic technologies. A new advisory group, called AD Screening Discussion Group, has recommended screening for Alzheimer's as patients become eligible for Medicare. The COGNISION(TM) System being developed by Neuronetrix, Inc. is a new Alzheimer's screening technology which will be entering clinical trials in Q1 2008. The COGNISION(TM) System uses proprietary pattern recognition algorithms to classify the patient's brainwave responses based on similarities to known neurological disease profiles. The test is non- invasive, inexpensive, and can be performed in a doctor's office.

Neuronetrix, based in Louisville, KY, will revolutionize the treatment of patients with neurologic disorders by providing meaningful screening information to physicians early in the disease process. Its patent-pending COGNISION(TM) System will "for the first time, directly detect the cognitive deficits associated with Alzheimer's disease," according to K.C. Fadem, inventor of the COGNISION(TM) System.

Alzheimer's is a chronic neurodegenerative disease which afflicts roughly 5 million individuals in the United States. Traditionally, a diagnosis is only made once significant symptoms are present, often 2-4 years into the symptomatic phase of the disease.

"Routine screening is not currently a reality, but it is now appropriate to allow for this, based on the burgeoning senior population in our country and the immense cost to society," according to Dr. Paul R. Solomon, Professor, Department of Psychology and Neuroscience, Williams College; and a member of the AD Screening Discussion Group.

Currently Alzheimer's patients incur direct Medicare/Medicaid costs of more than $50 billion per year, according to the Alzheimer's Association. Mike Reid, CEO of Neuronetrix, indicated that a conservative 5% penetration rate for COGNISION(TM) screening would represent almost $7 billion per year in Americans' cost savings for Alzheimer's care. These savings would be realized by delaying the point at which Alzheimer's sufferers would have to be placed in a long-term care facility. This delay will be due to earlier treatment with current Alzheimer's drugs such as Aricept(R) from Pfizer, Inc. and through treatment with potentially more effective drugs on the near term horizon.

The AD Screening Discussion Group is comprised of a multi-disciplinary panel of experts convened by Eisai Inc., and Pfizer, Inc., to debate the value of screening and early detection for Alzheimer's disease.

For more information, go to http://www.neuronetrix.com.


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... America held the largest share in the ECG ... population and demand for remote monitoring ECG devices. On the ... is expected to witness the highest growth rate during the ... (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... ) and Mindray Medical International Limited ( China ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
Breaking Medicine Technology: